Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Eslicarbazepine acetate (Aptiom) is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
• The information was derived from 8 systematic reviews/meta-analyses studies.
• In network meta-analysis, eslicarbazepine acetate showed effectiveness in decreasing seizure frequency but had a moderate safety profile compared to other ASMs like cenobamate, brivaracetam, lacosamide, and perampanel. Non-invasive brain stimulation therapies were less effective than ASMs.
• Real-world longitudinal studies demonstrated that eslicarbazepine acetate as initial or early monotherapy resulted in high seizure-free rates at 6 months (64.6%) and 12 months (56.6%), with retention rates at 95% and adverse events leading to discontinuation in some cases among adults with focal epilepsy.
• A Cochrane network meta-analysis could not include individual participant data for eslicarbazepine acetate; however, other drugs like lamotrigine performed better regarding treatment failure and achieving remission across children and adults with focal or generalized tonic-clonic seizures.
• Systematic review findings indicate that while eslicarbazepine acetate has acceptable safety profiles as an add-on therapy for drug-resistant focal epilepsy, it shows higher dropout rates due to adverse events when used among pediatric populations compared to drugs like lamotrigine and levetiracetam.